Company update is again nice and clear.The delivery of the final report on the successful Phase II trials triggers the six-month option period for Elanco to agree to the terms of the license agreement.
PharmAust said its management had worked with Elanco in the design of the clinical trials to help ensure that these trials, if successful, would provide sufficient data for Elanco to make the decision to exercise its option.
PAA / Elanco Count down
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)